open access

Vol 88, No 2 (2020)
CASE REPORTS
Published online: 2020-04-30
Submitted: 2019-10-08
Accepted: 2020-01-30
Get Citation

Pulmonary oxalosis in pulmonary aspergillosis syndrome

Oluwasegun S Osholowu, Vivek Kak, Harpreet Singh
DOI: 10.5603/ARM.2020.0090
·
Pubmed: 32383468
·
Adv Respir Med 2020;88(2):153-156.

open access

Vol 88, No 2 (2020)
CASE REPORTS
Published online: 2020-04-30
Submitted: 2019-10-08
Accepted: 2020-01-30

Abstract

The presence of pulmonary oxalosis in bronchoalveolar lavage (BAL) or biopsied tissue samples is considered pathognomonic for Aspergillus disease etiology. The finding of calcium oxalate crystals in the tissue samples infected with aspergillosis can serve as a vital diagnostic clue. Detection of calcium oxalate crystals is achievable within 24 hours by most hospital microbiology laboratories. It is much quicker than the time it takes to receive results of other tests like histopathology, sputum cultures, and aspergillus antigen assays. We present this case to emphasize the importance of pulmonary oxalosis as a crucial early diagnostic factor in pulmonary aspergillosis syndromes.

Abstract

The presence of pulmonary oxalosis in bronchoalveolar lavage (BAL) or biopsied tissue samples is considered pathognomonic for Aspergillus disease etiology. The finding of calcium oxalate crystals in the tissue samples infected with aspergillosis can serve as a vital diagnostic clue. Detection of calcium oxalate crystals is achievable within 24 hours by most hospital microbiology laboratories. It is much quicker than the time it takes to receive results of other tests like histopathology, sputum cultures, and aspergillus antigen assays. We present this case to emphasize the importance of pulmonary oxalosis as a crucial early diagnostic factor in pulmonary aspergillosis syndromes.

Get Citation

Keywords

aspergillosis; Aspergillus; oxalosis; calcium oxalate

Supplementary Files (1)
Cover letter
Download
12KB
About this article
Title

Pulmonary oxalosis in pulmonary aspergillosis syndrome

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 2 (2020)

Pages

153-156

Published online

2020-04-30

DOI

10.5603/ARM.2020.0090

Pubmed

32383468

Bibliographic record

Adv Respir Med 2020;88(2):153-156.

Keywords

aspergillosis
Aspergillus
oxalosis
calcium oxalate

Authors

Oluwasegun S Osholowu
Vivek Kak
Harpreet Singh

References (13)
  1. Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011; 20(121): 156–174.
  2. Grahame-Clarke CN, Roberts CM, Empey DW. Chronic necrotizing pulmonary aspergillosis and pulmonary phycomycosis in cystic fibrosis. Respir Med. 1994; 88(6): 465–468.
  3. Binder RE, Faling LJ, Pugatch RD, et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore). 1982; 61(2): 109–124.
  4. Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc. 2005; 2(5): 428–432.
  5. Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect. 2010; 61(5): 410–418.
  6. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016; 47(1): 45–68.
  7. Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4): e1–e60.
  8. Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis. 2012; 31(11): 3231–3239.
  9. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol. 2005; 43 Suppl 1: S207–S238.
  10. Denning DW, Riniotis K, Dobrashian R, et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis. 2003; 37 Suppl 3: S265–S280.
  11. Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest. 2007; 131(5): 1435–1441.
  12. Jain LR, Denning DW. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect. 2006; 52(5): e133–e137.
  13. Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4): e1–e60.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl